BE trial design as partial replicate and two stage [Regulatives / Guidelines]

posted by Silva – Portugal, 2014-04-17 11:36 (4453 d 18:29 ago) – Posting: # 12848
Views: 2,872

Hi Helmut
Once I met someone with the same doubts and he told me that he have asked for a CHMP SA on the subject. As I remember from the talk, his opinion was that the agency was also not able to deal with this complex statistical analysis and therefore the advice was to consider the second stage group as a group effect and therefore only 90% CI's were calculated and not the 94.12%!

But this is not mandatory, as no public information is available!

Rgs


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
344 visitors (0 registered, 344 guests [including 15 identified bots]).
Forum time: 06:06 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5